AstraZeneca
4Q Revenues: $14.9 billion (+24%)
4Q Earnings: $1.5 billion (+56%)
FY Revenues: $54.1 billion (+18%)
FY Earnings: $7.0 billion (+18%)
Comments: Oncology sales were $22.4 billion, up 21%. Tagrisso sales were $1.7 billion in the quarter, up 20%. Imfinzi sales were $1.3 billion, up 16%. Lynparza sales were up 46% to $1.4 billion.

Cardiovascular, Renal and Metabolism (CVRM) sales were up 16% in the quarter. Farxiga sales were up 21% to $1.9 billion. Brilinta sales were $341 million, up 4%. Crestor sales were up 5% to $261 million.

Respiratory & Immunology (R&I) sales in the quarter were up 27% to $2.1 billion. Symbicort sales were $684 million, up 31%. Fasenra sales were up 12% to $471 million. Breztri sales were up 29% to $257 million. This growth offset declines for Pulmicort, down 25% to $164 million.

Vaccines and Immune Therapies (V&I) sales were $651 million, up 58% driven by Beyfortus with $403 million in sales, offsetting losses for Synagis, down 38% to $101 million, and COVID mAbs.

Rare disease revenue was up 21% to $2.4 billion. Ultomiris sales were up 32% to $1.1 billion. Soliris sales were down 24% to $543 million. Strensiq sales were $420 million, up 38%.

Total Revenue by medicine includes Alliance Revenue and Collaboration Revenue within each revenue figure.